Risk Factors for Acute Kidney Injury Following Cardiac Catheterization


1. Blackman DJ, Pinto R, Ross JR, et al., Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention, Am Heart J, 2006;151(1):146–52.


2. Lindsay J, Apple S, Pinnow EE, et al., Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine, Catheter Cardiovasc Interv, 2003;59(3):338–43.


3. McCullough PA, Adam A, Becker CR, et al., Epidemiology and prognostic implications of contrast-induced nephropathy, Am J Cardiol, 2006;98(6A):5K–13K.


4. Bartorelli AL, Marenzi G, Contrast-induced nephropathy, J Interv Cardiol, 2008;21(1):74–85.


5. Mehran R, Contrast-induced nephropathy remains a serious complication of PCI, J Interv Cardiol, 2007;20(3):236–40.


6. Rihal CS, Textor SC, Grill DE, et al., Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention, Circulationm 2002;105(19):2259–64.


7. Marenzi G, Marana I, Lauri G, et al., The prevention of radiocontrast-agent-induced nephropathy by hemofiltration, N Engl J Med, 2003;349(14):1333–40.


8. Oldemeyer JB, Biddle WP, Wurdeman RL, et al., Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography, Am Heart J, 2003;146(6):1089–94.


9. Chertow GM, Burdick E, Honour M, et al., Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients, J Am Soc Nephrol, 2005;16(11):3365–70.


10. Pucelikova T, Dangas G, Mehran R, Contrast-induced nephropathy, Catheter Cardiovasc Interv, 2008;71(1):62–72.


11. McCullough PA, Adam A, Becker CR, et al., Risk prediction of contrast-induced nephropathy, Am J Cardiol, 2006;98(6A):27K–36K.


12. McCullough PA, Wolyn R, Rocher LL, et al., Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality, Am J Med, 1997;103(5):368–75.


13. Brown JR, Robb JF, Block CA, et al., Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury?, Circ Cardiovasc Interv, 2010;3(4):346–50.


14. Saklayen MG, Gupta S, Suryaprasad A, Azmeh W, Incidence of atheroembolic renal failure after coronary angiography. A prospective study, Angiology, 1997;48(7):609–13.


15. Scolari F, Ravani P, Pola A, et al., Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study, J Am Soc Nephrol, 2003;14(6):1584–90.


16. Theriault J, Agharazzi M, Dumont M, et al., Atheroembolic renal failure requiring dialysis: potential for renal recovery? A review of 43 cases, Nephron Clin Pract, 2003;94(1):c11–8.


17. Barrett BJ, Parfrey PS, Clinical practice. Preventing nephropathy induced by contrast medium, N Engl J Med, 2006;354(4):379–86.


18. Mehran R, Nikolsky E, Contrast-induced nephropathy: definition, epidemiology, and patients at risk, Kidney Int Suppl, 2006(100):S11–5.


19. Brown JR, DeVries JT, Piper WD, et al., Serious renal dysfunction after percutaneous coronary interventions can be predicted, Am Heart J, 2008;155(2):260–6.


20. Bartholomew BA, Harjai KJ, Dukkipati S, et al., Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification, Am J Cardiol, 2004;93(12):1515–9.


21. Mehran R, Aymong ED, Nikolsky E, et al., A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation, J Am Coll Cardiol, 2004;44(7):1393–9.


22. McCoy AB, Waitman LR, Gadd CS, et al., A computerized provider order entry intervention for medication safety during acute kidney injury: a quality improvement report, Am J Kidney Dis, 2010;56(5):832–41.


23. Matheny ME, Miller RA, Ikizler TA, et al., Development of inpatient risk stratification models of acute kidney injury for use in electronic health records, Med Decis Making, 2010;30(6):639–50.


24. Shahian DM, Torchiana DF, Shemin RJ, et al., Massachusetts cardiac surgery report card: implications of statistical methodology, Ann Thorac Surg, 2005;80(6):2106–13.


25. Glance LG, Dick A, Osler TM, et al., Impact of changing the statistical methodology on hospital and surgeon ranking: the case of the New York State cardiac surgery report card, Med Care, 2006;44(4):311–9.


26. Matheny ME, Ohno-Machado L, Resnic FS, Monitoring device safety in interventional cardiology, J Am Med Inform Assoc, 2006;13(2):180–7.


27. Resnic FS, Gross TP, Marinac-Dabic D, et al., Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices, JAMA, 2010;304(18):2019–27.


28. Barringhaus KG, Zelevinsky K, Lovett A, et al., Impact of independent data adjudication on hospital-specific estimates of risk-adjusted mortality following percutaneous coronary interventions in massachusett, Circ Cardiovasc Qual Outcomes, 2011;4(1):92–8.


29. Ettinger WH, Hylka SM, Phillips RA, et al., When things go wrong: the impact of being a statistical outlier in publicly reported coronary artery bypass graft surgery mortality data, Am J Med Qual, 2008;23(2):90–5.


30. Bouzas-Mosquera A, Vazquez-Rodriguez JM, Calvino-Santos R, et al., Contrast-induced nephropathy and acute renal failure following emergent cardiac catheterization: incidence, risk factors and prognosis, Rev Esp Cardiol, 2007;60(10):1026–34.


31. Soofi MA, Frequency of Acute Renal Failure after Cardiac Catheterization and Percutaneous Intervention, Pak J Med Sci, 2006;22(4):446–50.


32. Hennessy SA, LaPar DJ, Stukenborg GJ, et al., Cardiac catheterization within 24 hours of valve surgery is significantly associated with acute renal failure, J Thorac Cardiovasc Surg, 2010;140(5):1011–7.


33. Gupta R, Gurm HS, Bhatt DL, et al., Renal failure after percutaneous coronary intervention is associated with high mortality, Catheter Cardiovasc Interv, 2005;64(4):442–8.


34. Morcos SK, Thomsen HS, European Society of Urogenital R. European Society of Urogenital Radiology guidelines on administering contrast media, Abdom Imaging, 2003;28(2):187–90.


35. Bellomo R, Ronco C, Kellum JA, et al., Acute Dialysis Quality Initiative w. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group, Crit Care, 2004;8(4):R204–12.


36. Mehta RL, Kellum JA, Shah SV, et al., Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury, Crit Care, 2007;11(2):R31.


37. Gruberg L, Mehran R, Dangas G, et al., Acute renal failure requiring dialysis after percutaneous coronary interventions, Catheter Cardiovasc Interv, 2001;52(4):409–16.


38. Iakovou I, Dangas G, Mehran R, et al., Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention, J Invasive Cardiol, 2003;15(1):18–22.


39. Neyra J, Jacobsen G, Novak JE, Are Women at Higher Risk to Develop Radiocontrast-induced nephropathy (RCIN) following coronary angiography?, Presented at: National Kidney Foundation 2011, Washington, DC, April 26–30, 2011.


40. U S Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, 2010. Available at: www.usrds.org/adr.htm (accessed June 26, 2011).


41. Gruberg L, Mintz GS, Mehran R, et al., The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency, J Am Coll Cardiol, 2000;36(5):1542–8.


42. Prins JM, Buller HR, Kuijper EJ, et al., Once versus thrice daily gentamicin in patients with serious infections, Lancet, 1993;341(8841):335–9.


43. Freeman RV, O'Donnell M, Share D, et al., Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose, Am J Cardiol, 2002;90(10):1068–73.


44. Maioli M, Toso A, Gallopin M, et al., Preprocedural score for risk of contrast-induced nephropathy in elective coronary angiography and intervention, J Cardiovasc Med (Hagerstown), 2010;11(6):444–9.


45. Madsen TE, Pearson RR, Muhlestein JB, et al., Risk of nephropathy is not increased by the administration of larger volume of contrast during coronary angiography, Crit Pathw Cardiol, 2009;8(4):167–71.


46. Stolker JM, McCullough PA, Rao S, et al., Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography, J Am Coll Cardiol, 2010;55(14):1433–40.


47. Kosiborod M, Rathore SS, Inzucchi SE, et al., Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes, Circulation, 2005;111(23):3078–86.


48. Kosiborod M, Inzucchi SE, Krumholz HM, et al., Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk, Circulation, 2008;117(8):1018–27.


49. Gleeson TG, Bulugahapitiya S, Contrast-Induced Nephropathy, Am J Roentgenol, 2004;183(6):1673–89.


50. Marenzi G, Lauri G, Assanelli E, et al., Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction, J Am Coll Cardiol, 2004;44(9):1780–5.


51. Dangas G, Iakovou I, Nikolsky E, et al., Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables, Am J Cardiol, 2005;95(1):13–9.


52. Cigarroa RG, Lange RA, Williams RH, Hillis LD, Dosing of contrast material to prevent contrast nephropathy in patients with renal disease, Am J Med, 1989;86(6 Pt 1):649–52.


53. Marenzi G, Assanelli E, Campodonico J, et al., Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality, Ann Intern Med, 2009;150(3):170–7.


54. Brown JR, Robb JF, Block CA, et al., Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury?, Circ Cardiovasc Interv, 2010;3(4):346–50.


55. Solomon R, Nephrotoxicity of iodixanol versus iopamidol inpatients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures, Am Heart J, 2010;159(2):e7; author reply e9.


56. Hernandez F, Mora L, Garcia-Tejada J, et al., Comparison of


iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty, Rev Esp Cardiol, 2009;62(12):1373–80.


57. Reed M, Meier P, Tamhane UU, et al., The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta- analysis of randomized controlled trials, JACC Cardiovasc Interv, 2009;2(7):645–54.


58. Wessely R, Koppara T, Bradaric C, et al., Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention, Circ Cardiovasc Interv, 2009;2(5):430–7.


59. Pannu N, Wiebe N, Tonelli M, Alberta Kidney Disease N. Prophylaxis strategies for contrast-induced nephropathy, JAMA, 2006;295(23):2765–79.


60. Zoungas S, Ninomiya T, Huxley R, et al., Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy, Ann Intern Med, 2009;151(9):631–8.


61. Meier P, Ko DT, Tamura A, et al., Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis, BMC Med, 2009;7:23.


62. Kanbay M, Covic A, Coca SG, et al., Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials, Int Urol Nephrol, 2009;41(3):617–27.


63. Calabro P, Bianchi R, Caprile M, et al., Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography, Minerva Cardioangiol, 2010;58(1):35–40.


64. Hou SH, Bushinsky DA, Wish JB, et al., Hospital-acquired renal insufficiency: a prospective study, Am J Med, 1983;74(2):243–8.


65. Hatala R, Dinh TT, Cook DJ, Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review, Clin Infect Dis, 1997;24(5):810–5.


66. Hock R, Anderson RJ, Prevention of drug-induced nephrotoxicity in the intensive care unit, J Crit Care, 1995;10(1):33–43.


67. Taber SS, Mueller BA, Drug-Associated Renal Dysfunction, Critical Care Clinics, 2006;22(2):357.


68. Tran DD, Oe PL, de Fijter CW, van der Meulen J, Cuesta MA. Acute renal failure in patients with acute pancreatitis: prevalence, risk factors, and outcome, Nephrol Dial Transplant, 1993;8(10):1079–84.


69. Walsh TJ, Hiemenz JW, Seibel NL, et al., Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases, Clin Infect Dis, 1998;26(6):1383–96.


70. Whelton A, Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications, Am J Med, 1999;106(5B):13S–24S.


71. Perazella MA, Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity, Am J Med Sci, 2003;325(6):349–62.


72. Louis BM, Hoch BS, Hernandez C, et al., Protection from the nephrotoxicity of contrast dye, Ren Fail, 1996;18(4):639–46.


73. Kiski D, Stepper W, Brand E, et al., Impact of renin-angiotensin- aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium- induced nephropathy: a post-hoc analysis from the Dialysis- versus-Diuresis (DVD) trial, Nephrol Dial Transplant, 2010;25(3):759–64.


74. Gupta RK, Kapoor A, Tewari S, et al., Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study, Indian Heart J, 1999;51(5):521–6.


75. Yoshioka T, Fogo A, Beckman JK, Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion, Kidney Int, 1992;41(4):1008–15.


76. Parvez Z, Rahman MA, Moncada R, Contrast media-induced lipid peroxidation in the rat kidney, Invest Radiol, 1989;24(9):697–702.


77. Tepel M, van der Giet M, Schwarzfeld C, et al., Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine, N Engl J Med, 2000;343(3):180–4.


78. Nallamothu BK, Shojania KG, Saint S, et al., Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis, Am J Med, 2004;117(12):938–47.


79. Kelly AM, Dwamena B, Cronin P, et al., Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy, Ann Intern Med, 2008;148(4):284–94.


80. Trivedi H, Daram S, Szabo A, et al., High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy, Am J Med, 2009;122(9):874.


81. Conen D, Buerkle G, Perruchoud AP, et al., Hypertension is an independent risk factor for contrast nephropathy after percutaneous coronary intervention, Int J Cardiol, 2006;110(2):237–41.


82. Fukumoto Y, Tsutsui H, Tsuchihashi M, et al., The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study, J Am Coll Cardiol, 2003;42(2):211–6.


83. Brown JR, Kramer RS, Coca SG, Parikh CR, Duration of acute kidney injury impacts long-term survival after cardiac surgery, Ann Thorac Surg, 2010;90(4):1142–8.


84. Solomon RJ, Mehran R, Natarajan MK, et al., Contrast-induced nephropathy and long-term adverse events: cause and effect?, Clin J Am Soc Nephrol, 2009;4(7):1162–9.


US NEPHROLOGY 99


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84